Article info
Letter
Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis
- Correspondence to Noortje van Herwaarden, Department of Rheumatology, Sint Maartenskliniek, P.O. Box 9011, Nijmegen 6500 GM, The Netherlands; n.vanherwaarden{at}maartenskliniek.nl
Citation
Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis
Publication history
- Received April 20, 2015
- Revised August 2, 2015
- Accepted August 12, 2015
- First published September 4, 2015.
Online issue publication
November 10, 2015
Article Versions
- Previous version (4 September 2015).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/